Stockscreener 앱 받기
0.272
1.27%
-0.0035
시간 외 거래:
.27
-0.002
-0.74%
전일 마감가:
$0.2755
열려 있는:
$0.275
하루 거래량:
147.25K
Relative Volume:
0.28
시가총액:
$25.85M
수익:
$1.11M
순이익/손실:
$-6.45M
주가수익비율:
-3.4961
EPS:
-0.0778
순현금흐름:
$-6.26M
1주 성능:
-3.92%
1개월 성능:
+4.49%
6개월 성능:
-33.50%
1년 성능:
-12.71%
1일 변동 폭
$0.27
$0.2808
1주일 범위
$0.27
$0.30
52주 변동 폭
$0.242
$0.4985
IGC Pharma Inc Stock (IGC) Company Profile
명칭
IGC Pharma Inc
전화
301-983-0998
주소
4336 Montgomery Avenue, Bethesda, MD
Compare IGC vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
IGC
IGC Pharma Inc
|
0.272 | 26.18M | 1.11M | -6.45M | -6.26M | -0.0778 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.05 | 114.72B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
737.45 | 78.67B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
684.50 | 42.38B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
311.10 | 41.75B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
282.72 | 31.33B | 5.36B | 287.73M | 924.18M | 2.5229 |
IGC Pharma Inc 주식(IGC)의 최신 뉴스
IGC Pharma Reports Financial Results and Clinical Progress for the Period Ended December 31, 2025 - Hastings Tribune
IGC Achieves Major Milestone in Alzheimer's Trial Amid Financial Loss - GuruFocus
IGC Pharma’s AI-Driven Innovations and Patent Portfolio for Alzheimer’s Disease and Neuropsychiatric Treatments - Minichart
IGC to Showcase AI Platform for Alzheimer's Research at 2026 Con - GuruFocus
IGC Pharma : Annual Transition Report (Form 10-KT) - marketscreener.com
IGC Pharma to Showcase AI Platform with Alzheimer’s Disease Data Initiative at ADPD 2026 - BioSpace
IGC Pharma to Showcase AI Platform with Alzheimer's Disease Data Initiative at ADPD 2026 - PharmiWeb.com
AI tool aims to cut months from Alzheimer’s data prep at ADPD 2026 - Stock Titan
CEO Change: What is the Moat Score of IGC Pharma IncMarket Activity Recap & Real-Time Volume Analysis Alerts - baoquankhu1.vn
IGC Pharma (NYSEAMERICAN:IGC) Stock Price Down 1.2% – Time to Sell? - Defense World
IGC Pharma Adds Visionary Investigators Network as Clinical Site to Phase 2 CALMA Trial - Nasdaq
IGC Pharma Secures New Debt Financing for Liquidity - The Globe and Mail
IGC Stock Price, Quote & Chart | IGC PHARMA INC (NYSEARCA:IGC) - ChartMill
IGC Pharma Secures ~$526K in Financing, Including Default-Convertible Note With Vanquish - TradingView
How IGC Pharma Inc. stock compares to growth peersDollar Strength & Smart Money Movement Tracker - Naître et grandir
EPS Watch: Should value investors consider IGC Pharma IncJuly 2025 Setups & Fast Momentum Entry Tips - baoquankhu1.vn
IGC Pharma, Inc. announced that it has received $0.307 million in funding - marketscreener.com
IGC Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
IGC Should I Buy - Intellectia AI
IGC Pharma Files Utility Patent Applications Covering AI-Based Data Harmonization Architecture Suppo - PharmiWeb.com
IGC Pharma Files Utility Patent Applications Covering AI-Based Data Harmonization Architecture Supporting Alzheimer's Research - Nasdaq
Inside IGC Pharma’s AI push to clean up Alzheimer’s data - Stock Titan
IGC PE Ratio & Valuation, Is IGC Overvalued - Intellectia AI
FOMO Trade: What is the Moat Score of IGC Pharma IncBond Market & Verified Momentum Stock Ideas - baoquankhu1.vn
Trend Report: What is the Moat Score of IGC Pharma IncJuly 2025 Recap & Stepwise Trade Signal Implementation - baoquankhu1.vn
IGC Pharma Notes Updated Research Coverage from Ascendiant Capital Markets - The Globe and Mail
Aug Final Week: Is IGC Pharma Inc a cyclical or defensive stockWatch List & Real-Time Sentiment Analysis - baoquankhu1.vn
IGC Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
IGC Pharma expands Phase 2 CALMA trial with new clinical site - Yahoo Finance
IGC Pharma (NYSEAMERICAN:IGC) Price Target Raised to $5.00 at Ascendiant Capital Markets - Defense World
IGC Enhances Alzheimer's Trial with New Clinical Research Collab - GuruFocus
Miami neurology network joins Alzheimer’s agitation drug trial - Stock Titan
Will IGC Pharma Inc. stock go up in YEARDay Trade & Daily Momentum Trading Reports - mfd.ru
Trend Review: Will IGC Pharma Inc benefit from green energy policiesJuly 2025 PreEarnings & Weekly Watchlist of Top Performers - baoquankhu1.vn
IGC: CALMA trial nears completion and MINT-AD AI platform set for beta launch amid favorable regulations - TradingView
IGC: Alzheimer's drug trial nears completion as AI dementia tool readies for beta launch - TradingView
Is IGC Pharma Inc. stock a buy before product launchesJuly 2025 Movers & Long Hold Capital Preservation Tips - mfd.ru
IGC Pharma Secures North American Composition Protection for IGC-AD1 as Phase 2 CALMA Enrollment Advances - GuruFocus
Low-dose THC Alzheimer’s drug from IGC wins key North America patent - Stock Titan
IGC Pharma to Participate in Fireside Chat With Ascendiant Capital Markets - Finviz
Is IGC Pharma Inc. likely to announce a buybackJuly 2025 Market Mood & Daily Entry Point Alerts - mfd.ru
Aug Catalysts: Should I trade or invest in IGC Pharma IncJuly 2025 Intraday Action & Stepwise Swing Trade Plans - baoquankhu1.vn
Why IGC Pharma Inc. (IGS1) stock could rally stronglyJuly 2025 Breakouts & Accurate Entry and Exit Point Alerts - mfd.ru
IGC Pharma Announces Equity Research Update by Alliance Global Partners - BioSpace
IGC Pharma Announces Equity Research Update by Alliance Global P - GuruFocus
IGC Pharma Expands Phase 2 CALMA Trial into Colombia's Premier Alzheimer's Research Center - BioSpace
IGC Pharma Expands Phase 2 CALMA Trial into Colombia's Premier A - GuruFocus
IGC Pharma Expands Key Alzheimer's Trial into Colombia - GuruFocus
IGC Pharma Inc (IGC) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.20%
0.06%
자본화:
|
볼륨(24시간):